Novel Chalcone-Based Chemotherapeutic Compound for Triple Negative Breast Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,746,104 | Novel Chalcone-Based Chemotherapeutic Compound for Triple Negative Breast Cancer In force · High confidence | Qatar University | In force | High confidence | ||
| US 12,428,405 | Novel Chalcone-Based Chemotherapeutic Compound for Triple Negative Breast Cancer In force · High confidence | Qatar University | In force | High confidence | ||
| Application 19/319,142 | Chalcone-Based Chemotherapeutic Compounds and Treatments for Cancer Pending Not granted | Qatar University | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Qatar University.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.